APPENDICES. A systematic review and economic model of the ...

306
Appendix 12
Core symptoms Educational performance Quality of life Adverse events
Withdrawals:
All discontinuations were due to adverse events (9 in
ATX group and 1 in placebo group)
ADHD Rating Scale IV: total score
(baseline/change from baseline)
ATX: 15.8 (9.6)/6.8 (13.6)
Placebo: 15.7 (10.0)/12.3 (14.3)
(ATX > placebo, F = 15.58, p < 0.001)
The authors state that gastroenteritis and pharyngitis
were more common on ATX, whereas increased
appetite was more common on placebo (reported by
≥ 5% in either group). Patients on ATX gained weight
more slowly than on placebo: absolute increase in
kilograms for ATX 1.2 (2.4) and placebo 3.3 (3.6),
p < 0.001
Not reported CGI Severity of Illness scale
(baseline/change from
baseline)
ATX: 2.3 (1.0)/0.9 (1.6)
Placebo: 2.2 (0.9)/1.4 (1.6)
(ATX > placebo, F = 9.13,
p = 0.003)
Child Health Questionnaire
psychosocial summary score
(baseline/change from
baseline)
ATX (n = 235): 43.4
(10.0)/–5.6 (13.2)
Placebo (n = 96): 44.0
(8.6)/–9.5 (12.0) (ATX >
placebo, F = 5.83, p = 0.016)
ADHD Rating Scale IV : inattentive symptoms
(baseline/change from baseline)
ATX: 8.6 (5.1)/3.7 (7.4)
Placebo: 8.6 (5.4)/6.4 (7.7) (ATX > placebo,
F = 14.17, p < 0.001)
ADHD Rating Scale IV: hyperactive/impulsive
symptoms (baseline/change from baseline)
ATX: 7.2 (5.5)/3.1 (7.0)
Placebo: 7.1 (5.5)/5.9 (7.4) (ATX > placebo,
F = 13.37, p < 0.001)
CPRS: hyperactivity (baseline/change from
baseline)
ATX: 4.5 (3.8)/1.5 (4.7)
Placebo: 4.6 (4.2)/3.1 (4.9) (ATX > placebo,
F = 10.25, p = 0.001)
CTRS: hyperactivity (baseline/change from
baseline)
ATX (n = 228): 7.7 (5.1)/0.4 (5.2)
Placebo (n = 93): 8.1 (5.5)/1.4 (4.6)
(NS, F = 3.1, p =0.079)
Conclusions Authors’ conclusions: In patients who responded favourably to 12 weeks of initial treatment, ATX was superior to placebo in
maintaining response for the ensuing 9 months
Reviewer’s comments: No comments noted